© 2001 by Oxford University Press
Journal of the National Cancer Institute Monographs, No. 30, 96-102,
2001
© 2001 Oxford University Press
Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18
Affiliations of authors: N. Wolmark, National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh; J. Wang, NSABP Biostatistical Center and Department of Biostatistics, University of Pittsburgh; E. Mamounas, NSABP Breast Committee and Aultman Cancer Center, Canton, OH; J. Bryant, NSABP Biostatistical Center and Departments of Biostatistics and Statistics, University of Pittsburgh; B. Fisher, NSABP and Department of Surgery, University of Pittsburgh.
Correspondence to: Norman Wolmark, M.D., 320 E. North Ave., Pittsburgh, PA 15212 (e-mail: nwolmark{at}wpahs.org).
National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was initiated in 1988 to determine whether four cycles of doxorubicin/cyclophosphamide given preoperatively improve survival and disease-free survival (DFS) when compared with the same chemotherapy given postoperatively. Secondary aims included the evaluation of preoperative chemotherapy in downstaging the primary breast tumor and involved axillary lymph nodes, the comparison of lumpectomy rates and rates of ipsilateral breast tumor recurrence (IBTR) in the two treatment groups, and the assessment of the correlation between primary tumor response and outcome. Initially published findings were based on a follow-up of 5 years; this report updates results through 9 years of follow-up. There continue to be no statistically significant overall differences in survival or DFS between the two treatment groups. Survival at 9 years is 70% in the postoperative group and 69% in the preoperative group (P = .80). DFS is 53% in postoperative patients and 55% in preoperative patients (P = .50). A statistically significant correlation persists between primary tumor response and outcome, and this correlation has become statistically stronger with longer follow-up. Patients assigned to preoperative chemotherapy received notably more lumpectomies than postoperative patients, especially among patients with tumors greater than 5 cm at study entry. Although the rate of IBTR was slightly higher in the preoperative group (10.7% versus 7.6%), this difference was not statistically significant. Marginally statistically significant treatment-by-age interactions appear to be emerging for survival and DFS, suggesting that younger patients may benefit from preoperative therapy, whereas the reverse may be true for older patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. P. Mamounas Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings Ann. Surg. Oncol., March 1, 2008; 15(3): 691 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg, A. Robidoux, R. G. Margolese, J. L. Hoehn, V. G. Vogel, S. R. Dakhil, et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J. Clin. Oncol., February 10, 2008; 26(5): 778 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Gralow, H. J. Burstein, W. Wood, G. N. Hortobagyi, L. Gianni, G. von Minckwitz, A. U. Buzdar, I. E. Smith, W. F. Symmans, B. Singh, et al. Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease J. Clin. Oncol., February 10, 2008; 26(5): 814 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. C. Ellis Neoadjuvant Therapy for Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 55 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dawood, K. Broglio, S.-W. Kau, R. Islam, W. F. Symmans, T. A. Buchholz, S. E. McGuire, F. Meric-Bernstam, M. Cristofanilli, G. N. Hortobagyi, et al. Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response Oncologist, January 1, 2008; 13(1): 6 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hudis and S. Modi Preoperative Chemotherapy for Breast Cancer: Miracle or Mirage? JAMA, December 12, 2007; 298(22): 2665 - 2667. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Newman, M. S. Sabel, A. V. Nees, A. Schott, K. M. Diehl, V. M. Cimmino, A. E. Chang, C. Kleer, D. F. Hayes, and L. A. Newman Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation Ann. Surg. Oncol., October 1, 2007; 14(10): 2946 - 2952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Lee, B. A. Moffat, A. F. Schott, R. Layman, S. Ellingworth, R. Juliar, A. P. Khan, M. Helvie, C. R. Meyer, T. L. Chenevert, et al. Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy Clin. Cancer Res., January 15, 2007; 13(2): 443 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372. [Abstract] [Full Text] [PDF]
|
|